These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 25234340)

  • 21. Pharmacogenetic approaches to cognitive enhancement in schizophrenia.
    Burdick KE; Gopin CB; Malhotra AK
    Harv Rev Psychiatry; 2011; 19(3):102-8. PubMed ID: 21631157
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Serotonin and dopamine interactions in rodents and primates: implications for psychosis and antipsychotic drug development.
    Marek GJ
    Int Rev Neurobiol; 2007; 78():165-92. PubMed ID: 17349861
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Alternative pharmacologic targets for the treatment of schizophrenia: results from phase I and II trials.
    Miyamoto S; Jarskog LF; Fleischhacker WW
    Curr Opin Psychiatry; 2013 Mar; 26(2):158-65. PubMed ID: 23286991
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2009 Aug; 63(8):1237-48. PubMed ID: 19624791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Serotonin-dopamine antagonists and treatment of negative symptoms.
    Carpenter WT
    J Clin Psychopharmacol; 1995 Feb; 15(1 Suppl 1):30S-35S. PubMed ID: 7730498
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Schizophrenia drug gets negative results for negative symptoms.
    Kingwell K
    Nat Rev Drug Discov; 2014 Apr; 13(4):244-5. PubMed ID: 24687052
    [No Abstract]   [Full Text] [Related]  

  • 27. Serotonin and dopamine interactions in psychosis prevention.
    Richtand NM; McNamara RK
    Prog Brain Res; 2008; 172():141-53. PubMed ID: 18772031
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Functional role of dopamine D4 receptor in schizophrenia].
    Semba J
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2004 Feb; 24(1):13-20. PubMed ID: 15027326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Inflammatory processes in schizophrenia: a promising neuroimmunological target for the treatment of negative/cognitive symptoms and beyond.
    Meyer U; Schwarz MJ; Müller N
    Pharmacol Ther; 2011 Oct; 132(1):96-110. PubMed ID: 21704074
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Emerging 5-HT receptor antagonists for the treatment of Schizophrenia.
    Jones MT; Strassnig MT; Harvey PD
    Expert Opin Emerg Drugs; 2020 Jun; 25(2):189-200. PubMed ID: 32449404
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Targeting metabotropic glutamate receptors to develop novel antipsychotics].
    Chaki S; Yoshida S; Okuyama S
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2010 Nov; 30(5-6):207-13. PubMed ID: 21226317
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Targeting cognitive deficits in schizophrenia: a review of the development of a new class of medicines from the perspective of community mental health researchers.
    Tcheremissine OV; Castro MA; Gardner DR
    Expert Opin Investig Drugs; 2012 Jan; 21(1):7-14. PubMed ID: 22059602
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Drug initiatives to improve cognitive function.
    Marder SR
    J Clin Psychiatry; 2006; 67 Suppl 9():31-5; discussion 36-42. PubMed ID: 16965187
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lurasidone for schizophrenia: a review of the efficacy and safety profile for this newly approved second-generation antipsychotic.
    Citrome L
    Int J Clin Pract; 2011 Feb; 65(2):189-210. PubMed ID: 21129135
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Maintenance therapy and the natural course of schizophrenia.
    Davis JM
    J Clin Psychiatry; 1985 Nov; 46(11 Pt 2):18-21. PubMed ID: 2865252
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Bl-1020, a new γ-aminobutyric acid-enhanced antipsychotic: results of 6-week, randomized, double-blind, controlled, efficacy and safety study.
    Geffen Y; Keefe R; Rabinowitz J; Anand R; Davidson M
    J Clin Psychiatry; 2012 Sep; 73(9):e1168-74. PubMed ID: 23059159
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Risperidone: an analysis of the first three years in general use.
    Gutierrez-Esteinou R; Grebb JA
    Int Clin Psychopharmacol; 1997 Sep; 12 Suppl 4():S3-10. PubMed ID: 9352340
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Drug safety and efficacy evaluation of sertindole for schizophrenia.
    Karamatskos E; Lambert M; Mulert C; Naber D
    Expert Opin Drug Saf; 2012 Nov; 11(6):1047-62. PubMed ID: 22992213
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Randomized trial to evaluate the efficacy of cognitive therapy for low-functioning patients with schizophrenia.
    Grant PM; Huh GA; Perivoliotis D; Stolar NM; Beck AT
    Arch Gen Psychiatry; 2012 Feb; 69(2):121-7. PubMed ID: 21969420
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.